Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Margetuximab
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : MacroGenics
Deal Size : $75.0 million
Deal Type : Acquisition
MacroGenics Enters into Agreement with TerSera Therapeutics for The Sale of MARGENZA®
Details : Under the agreement, TerSera will acquire global rights to Margenza (margetuximab) from MacroGenics. It is indicated for the treatment of HER2-positive breast cancer.
Brand Name : Margenza
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : Margetuximab
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : MacroGenics
Deal Size : $75.0 million
Deal Type : Acquisition
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Approves ZOLADEX LA for ER-Positive Breast Cancer in Premenopausal Women
Details : Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.
Brand Name : Zoladex
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 07, 2024
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Brand Name : Xermelo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : First randomized, double-blind, controlled trial evaluating IV cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions. QUZYTTIR is the first and only injectable second-generation H1 antihistamine to be approved by t...
Brand Name : Quzyttir
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 05, 2021
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?